

Exploring key drivers in cancer risk: Unveiling disparities

Dr. Ayşe Arık

Department of Actuarial Mathematics and Statistics, Heriot-Watt University, and the
Maxwell Institute for Mathematical Sciences, UK

joint work with Andrew Cairns, Erengul Dodd, Angus S Macdonald, Adam Shao, and George
Streftaris

Funding from:

Predictive Modelling for Medical Morbidity Risk Related to Insurance – SoA
Estimating The Impact Of The COVID-19 Pandemic On Breast Cancer Deaths - An
Application On Breast Cancer Life Insurance – SCOR Foundation for Science



- 1 Part 1: What we have done in the SCOR-funded project
 - (Semi-)Markov model for breast cancer
 - Summary (1)

- 2 Part 2: Earlier cancer-related research
 - Bayesian modelling for cancer risk
 - Insights gained from the population data of England

- 3 Part 3: Ongoing cancer-related research
 - Projection of cancer mortality
 - Summary (2)

Funded project:

Breast cancer (BC) as it is

- **the most common** cancer diagnosed in women
- **one of the leading causes** of death for women
- one of the most **common** conditions amongst **critical illness insurance (CII) claims**, e.g. 44% of female CII claims in 2014 in the UK


Investigating BC rates in the presence of:

- major disruptions to health services, **particularly caused by a catastrophic event**, e.g. the **COVID-19**, preventing or delaying the diagnosis of BC

Examining the related insurance products:

- actuarial fair premiums

A versatile semi-Markov model



- Duration dependence in 'Pre-metastatic Diagnosed' and 'Pre-metastatic Unobserved'
- No treatment in 'Pre-metastatic Unobserved' $\Rightarrow \mu_{x,z}^{13} < \mu_{x,z}^{23}$

Summary (1)

- ① A valuable model relating to delays in the provision of BC diagnostic and treatment services
... also relevant to meet the needs of women with medical history of BC
- ② As compared to the pre-pandemic scenario
 - 3–6% increase in deaths from BC
 - 5–8% increase in deaths from other causesbetween ages 65–89
- ③ Flexible models are relevant to medical underwriting of related insurance contracts
- ④ Duration dependence matters in actuarial applications

Cancer data

Cancer incidence and deaths data England: Office for National Statistics (ONS)

- Age groups: 0, 1-4, 5-9, ..., 95+
Age-standardised results, based on the European Standard Population (ESP) 2013
- Gender
- Years: 2001–2018 (*some* up to 2022)
- Income Deprivation deciles or quintiles
 - 1: most deprived; 10: least deprived
 - 1: most deprived; 5: least deprived
- Regions of England: North East, North West, Yorkshire and the Humber, East Midlands, West Midlands, East, London, South East and South West

A separate stochastic modelling: Bayesian models for cancer rates

$$C_{a,t,d,g,r} \sim \text{Poisson}(\theta_{a,t,d,g,r} E_{a,t,d,g,r})$$

$$\theta_{a,t,d,g,r} \sim \text{Lognormal}(\mu_{a,t,d,g,r}, \sigma^2)$$


$$\mu_{a,t,d,g,r} = \beta' \mathbf{X}$$

$$\beta's \sim \text{Normal}(0, 10^4) \quad [\text{vague priors for risk factor effects}]$$

$$\sigma^2 \sim \text{Inv.Gamma}(1, 0.001)$$


- $C_{a,t,d,g,r}$: number of cancer registrations/deaths at **age** a , in **year** t , for **gender** g , **deprivation** level d and **region** r
- $E_{a,t,d,g,r}$: mid-year population estimates
- $\theta_{a,t,d,g,r}$: incidence/mortality rates
- \mathbf{X} : vector of covariates: **age**, **year**, **deprivation**, **gender**, **region**, **average age-at-diagnosis (AAD)** + appropriate interaction(s)
- β : vector of coefficients

Regional variation: BC mortality, 2018



✓ Rate is per 10K
✓ Deprivation is not significant

Most v. least deprived by region: LC mortality, women, 2017



- A life-style cancer
- Rates for **most deprived** much higher
- Regional variation

What insights we gain: (Arik et al., 2020, 2021, 2022)



Study points to big surge in under-50 cancer cases

6 September · Comments



The number of cancer cases among the under-50s around the world appears to have risen sharply in the past 30 years, a study suggests.

- **Age:** higher rates at older ages?
 - changing?
 - lifestyle factors?
- **Time:**
 - higher incidence in more recent years
 - lower mortality
- **Gender:** higher rates for men
- **Regional inequality** exists
- **Socio-economic differences** are more relevant to life-style cancers

A separate related research: Bayesian forecasting for cancer mortality

$$C_{a,t,d,g,r} \sim \text{Poisson}(\theta_{a,t,d,g,r} E_{a,t,d,g,r})$$

$$\theta_{a,t,d,g,r} \sim \text{Lognormal}(\mu_{a,t,d,g,r}, \sigma^2)$$

$$\mu_{a,t,d,g,r} = \beta_0 + \beta_{1,a} + \beta_{2,t} + \beta_{3,r} + \beta_{4,d} + \beta_5 \text{AAD}_{r,d} + \beta_6 \text{NS}_{a,t-20} + \text{interaction terms}$$

$$\beta' \sim \text{Normal}(0, 10^4) \quad [\text{vague priors for risk factor effects}]$$

$$\sigma^2 \sim \text{Inv.Gamma}(1, 0.1)$$

Add random walk with drift for 'period' effect:

$$\beta_{2,t} = \text{drift} + \beta_{2,t-1} + \epsilon_t$$

$$\text{drift} \sim \text{Normal}(0, \sigma_{\text{drift}}^2)$$



$$\epsilon_t \sim \text{Normal}(0, \sigma_{\beta_2}^2)$$

$$\sigma_{\beta_2}^2 \sim \text{Inv.Gamma}(1, 0.001)$$

for $t = 2002, \dots, 2036$, where $\hat{\sigma}_{\text{drift}}^2 = \frac{\hat{\sigma}_{\beta_2}^2}{2018-2001}$

Non-smoker prevalence rates: England, 1993–2019

Non-smoker (NS) prevalence observed (**dots**) and fitted (**solid line**) rates for men (**left**) and women (**right**)




Increasing trend for NS prevalence

... more evident in men

Reconstruct NS prevalence (**dashed**) backwards to 1981:


$$NS_{a,t} = \beta_0 + \beta_{1,a} + \beta_2 t + \beta_3 t^2 + \beta_{4,a} t$$

Projected mortality: BC, women, 2001–2036




- Decreasing trend over time
- AAD is *NOT* significant BUT smoking is
- Projected rates for youngest & oldest screening age groups *NOT* overlapping

Regional gap: BC, women, 2001–2036




- Significant improvement in mortality from 2001 to 2018
 - ... and persists in the future years
- Region is significant
 - ... yet ONLY marginal differences in mortality across regions

Projected mortality: LC, men, 2001–2036




- Deprivation quintiles
- Projected rates for most & least deprived *NOT* overlapping

Projected mortality: LC, women, 2001–2036



- Deprivation quintiles
- Mortality for women *NOT* always decreasing

Deprivation gap: LC, women, 2001–2036



- Widening deprivation gap from 2001 to 2018
... persists in the future years

- Relative mortality rate

$$\frac{\hat{\theta}_{t,\text{quintile } 1,r}}{\hat{\theta}_{t,\text{quintile } 5,r}}$$

- $\hat{\theta}_{t,d,r}$: age-standardised fitted mortality rates
- Comparable findings in men

Impact of diagnosis delays on mortality



Scottish cancer cases rise by 15% after pandemic drop

28 March



GETTY IMAGES

Breast cancer screening was paused in 2020 due to the Covid-19 pandemic

Cases of cancer in Scotland increased by almost 15% in a year after dropping in the first 12 months of the pandemic.

- Estimate average age-at-diagnosis (AAD) with incidence rates

$$AAD_{t,d,g,r} = \frac{\sum_a a \hat{\lambda}_{a,t,d,g,r} E_a^{\text{std}}}{\sum_a \hat{\lambda}_{a,t,d,g,r} E_a^{\text{std}}}$$

$$AAD_{d,g,r} = \frac{\sum_t AAD_{t,d,g,r} E_{t,d,g,r}}{\sum_t E_{t,d,g,r}}$$

- $\hat{\lambda}_{a,t,d,g,r}$: fitted incidence rates
- Include AAD as risk factor in mortality model

e.g.



$$\mu_{a,t,d,r} = \beta_0 + \beta_{1,a} + \beta_{2,t} + \beta_{3,r} + \beta_{4,d} + \beta_5 AAD_{d,r} + \beta_6 NS_{a,t-20}$$

- Estimate impact on mortality

Quantify COVID-19 impact on future mortality



- Assume increase in AAD from 2020
 - Use ONS region-based future population estimates
 - Assume future deprivation structure unchanged
 - The impact of an increase in AAD distributed over future years
- Fit Bayesian forecasting model:
 - under no change in AAD (baseline scenario)
 - under 1-month AAD increase (COVID scenario 1)
 - under 3-month AAD increase (COVID scenario 2)
 - under 6-month AAD increase (COVID scenario 3)
 - estimate excess deaths

Excess mortality by age: LC, men, 2020–2036



- Annual excess mortality due to 1-month **(left)** and 6-month **(right)** diagnosis delays
- LC is the leading cause of death for ages 65 to 79 (ONS, 2023)

Total excess deaths by region: LC, 2020–2036




Excess deaths due to 6-month diagnosis delay:

10,180 [7,944 to 12,340] (women) v.
28,660 [23,040 to 35,090] (men)

- Excess deaths in women (left) and men (right) due to 1-month, 3-month, and 6-month delays
- Excess mortality differs by region & deprivation

Excess mortality by deprivation: LC, women, 2020–2036



- Annual excess mortality due to 1-month (**left**) and 6-month (**right**) diagnosis delays
- Higher excess mortality in the most deprived quintile

Summary (2)

- ① Regional and socioeconomic gap for cancer rates is widening in England
... but not for all cancer types
- ② Smoking is significant to explain both BC and LC mortality
- ③ COVID-related delays in diagnoses can lead to significant increase in cancer deaths
 - age, region and deprivation dependent
- ④ Projection for LC mortality shows persistent deprivation gap
 - and significant excess deaths due to COVID-like disruptions

More details in:

- ① Arık, A. Estimation and projection of cancer mortality in England, SA0 project.
- ② Arık, A., Cairns, A., Dodd, E., Macdonald, A.S., Shao, A., Streftaris, G. Insurance pricing for breast cancer under different multiple state models, working paper.
- ③ Arık, A., Cairns, A., Dodd, E., Macdonald, A.S., Streftaris, G. The effect of the COVID-19 health disruptions on breast cancer mortality for older women: A semi-Markov modelling approach, <https://arxiv.org/abs/2303.16573>.
- ④ Arık, A., Cairns, A., Dodd, E., Macdonald, A.S., Streftaris, G. Estimating the impact of the COVID-19 pandemic on breast cancer deaths among older women, Living to 100 Research Symposium, 16 February 2023, conference monograph.
- ⑤ Arık, A., Dodd, E., Cairns, A., Streftaris, G. Socioeconomic disparities in cancer incidence and mortality in England and the impact of age-at-diagnosis on cancer mortality, PLOS ONE, 2021.
- ⑥ Arık, A., Dodd, E., Streftaris, G. Cancer morbidity trends and regional differences in England - a Bayesian Analysis, PLOS ONE, 2020.

Thank You!

Questions?

E: A.ARIK@hw.ac.uk

W: <https://researchportal.hw.ac.uk/en/persons/ayse-arik>